Supplier News: Avid Bio, Aragen, Quotient & More
The latest from CDMOs, CMOs, and suppliers featuring Avid Bioservices, Aragen, Integrated DNA Technologies, eXmoor and Quotient Sciences.
* Avid Bioservices Completes Cell- & Gene-Therapy Mfg Facility
* Aragen To Build New Biologics Mfg Facility
* Integrated DNA Technologies Opens Cell- & Gene-Therapy Mfg Facility
* eXmoor To Build $35-M Cell- & Gene-Therapy Mfg Facility
* Quotient Sciences Expands Sterile Fill-Finish Facility
Avid Bioservices Completes Cell- & Gene-Therapy Mfg Facility
Avid Bioservices, a Tustin, California-based CDMO of biologics, has completed construction of its new CGMP manufacturing suites within its new cell and gene therapy development and CGMP manufacturing facility.
The facility will have the capability to produce suspension culture batches of up to 3,000 liters, as well as adherent cultures utilizing fixed bed bioreactors. The facility has 6,000 square feet dedicated to quality control laboratory space.
Source: Avid Bioservices
Aragen To Build New Biologics Mfg Facility
Aragen, a Hyberadad, India-based CDMO of small molecules and biologics, announced a new biologics manufacturing facility in Bangalore, India.
The facility is part of a $30 million investment, spanning nearly 160,000 square meters, and includes process development labs and multiple GMP manufacturing suites. The manufacturing suites will be equipped for intensified processing using single-use bioreactors and downstream purification capability.
The facility will offer integrated solutions from process development, process validation, analytical development, pilot production, large-scale DS manufacturing and stability services. It will have the capability to develop and manufacture mAbs, therapeutic proteins and fusion proteins.
Integrated DNA Technologies Opens Cell- & Gene-Therapy Mfg Facility
Integrated DNA Technologies, a Coralville, Iowa-based CDMO, has completed its new manufacturing facility in Coralville, Iowa.
The 41,000-square-foot-site will produce cGMP cell and gene therapy reagents, including single guide RNAs (sgRNAs) and donor oligos for homology-directed repair. The facility has ISO 8 cleanrooms, purification suites, chemical distribution and storage rooms, quality control labs, analytical lab space for product testing, ancillary and office spaces and shell space for future expansion.
Source: Integrated DNA Technologies
eXmoor To Build $35-M Cell- & Gene-Therapy Mfg Facility
eXmoor pharma, a Bristol, UK-based CDMO of cell- & gene-therapies, has closed a $35 million Series A financing round, of which the funds will help launch a 65,000-square-foot GMP manufacturing facility.
The new facility, opening in Bristol in July 2023, will feature a mixture of manufacturing cleanrooms, process & analytical development and QC laboratories, and associated support spaces suitable for all types of cell- & gene-therapies.
Source: eXmoor pharma
Quotient Sciences Expands Sterile Fill-Finish Facility
Quotient Sciences, a Nottingham, UK-based CDMO, has made an investment in the sterile fill-finish capabilities at its Alnwick, UK facility.
As part of this expansion, the company has invested in a new isolator technology, enabling larger batch sizes and reduced cycle times per manufacturing campaign. The site also benefits from an integrated in-house microbiology team to accelerate testing and environmental monitoring, with further investment in the microbiology labs planned for next year.
Source: Quotient Sciences